Overexpression of CD30 has been reported on the surface of some T-cell lymphomas, especially on Hodgkin's lymphoma (HL) and anaplastic large cell lymphoma (ALCL). CD30 targeted immunotherapy has good clinical therapy response. We have produced a novel antibody drug conjugates (ADCs)-anti-CD30-LDM, which shows attractive tumour-targeting capability and extremely potent antitumor efficacy. To further investigate biological characteristics and promote clinical translation of anti-CD30-LDM, we constructed a radiolabeled 123 I-anti-CD30-LDM to evaluate the biodistribution characteristics. The anti-CD30-LDM was radioiodinated by the Iodogen method. The radiochemical purity of 123 I-anti-CD30-LDM was more over 98%, and the specific activity of 240.5 MBq/mg. The stability and the specificity of 123 I-anti-CD30-LDM were evaluated in vitro. Cellular binding assays were used to evaluate the binding capabilities in CD30-positive Karpas299 cells and CD30-negative Raji cells. B-NDG mice bearing Karpas 299 and Raji xenografts were used for in vivo biodistribution studies. Our results demonstrated that anti-CD30-LDM as an ideal ADC targeted to CD30, which was labelled easily with 123 I and obtained the sufficient yields. The 123 I-anti-CD30-LDM preserved specific binding to CD30 in vitro and uptake in tumour xenografts in B-NDG mice. These results are encouraging for anti-CD30-LDM as a promising clinical translational candidate for various CD30 positive lymphomas and other diseases.
Introduction
CD30 is a 120 kDa type I transmembrane glycoprotein belonging to the tumour necrosis factor receptor superfamily [1] . Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL). Recently, CD30-positive expression was also reported in other diseases [2, 3] . CD30-targeted immunotherapy has been used in the recurrent, or refractory HL/ALCL [4, 5] . The advent of antibody-drug conjugates (ADCs) has the potential to revolutionize the treatment of lymphoma [6] . ADCs are designed to bind to the precise targets on tumour cells and deliver cytotoxic agents after being internalized, thus, sparing normal cells and limiting toxicities. One of the most successful ADCs is Brentuximab vedotin (BV), an anti-CD30 ADCs the microtubule-disrupting agent monomethyl auristatin E (MMAE) by a protease-cleavable linker [7] . BV is a successful treatment for patients with certain types of lymphoma [8] . However, many patients do not achieve complete remission and eventually become resistant to BV treatment. Furthermore, MMAE resistance has been associated with resistance to BV [9] . Therefore, it is imperative to develop other cytotoxic agents that can be linked to ADCs.
Lidamycin (LDM) is a novel enediyne-containing antitumor antibiotic developed by our laboratory. LDM inhibits DNA synthesis and causes cellular DNA breakage in cancer cells [10] . It contains an active enediyne chromophore (AE) responsible for the extremely potent bioactivity and a noncovalently bound apoprotein LDP, which forms a hydrophobic pocket to protect the chromophore [11] . AE and LDP can be dissociated and reconstituted under certain conditions in vitro [12] .
We have previously described a novel ADC, anti-CD30-LDM [13] , which is comprised of two molecules of LDM linked to an anti-CD30 monoclonal antibody (mAb) via noncleavable linkers. Thus, the LDM is delivered to the CD30positive cancer cells by the mAb, causes DNA damage by inducing double-strand breaks, and results in cell cycle arrest and apoptosis [14, 15] . This ADC displays specific affinity and extremely potent cytotoxicity against CD30-overexpressing tumour cells in vitro, with IC 50 (half-maximal inhibitory concentration) values ranging from 0.54 Â 10 À11 to 3.74 Â 10 À11 M. In a Karpas299 xenograft model, tumour growth was inhibited by 87.76% in mice treated with 0.7 mg/kg anti-CD30-LDM [13] . The combination of anti-CD30-LDM with crizotinib exhibits a synergistic inhibitory antitumor effect in ALCL [16] . Based on the excellent characteristics of anti-CD30-LDMhigh binding capability and highly specific to CD30 antigen, extremely potent cytotoxicity against CD30overexpressing tumour cells, we further investigated the biodistribution of anti-CD30-LDM in the CD30-positive lymphoma models. Here, the labelling method and condition, physiochemical property, in vitro activity, in vivo biodistribution of anti-CD30-LDM were studied. The preliminary biodistribution data would provide the basis for further clinical translational research of anti-CD30-LDM. 
Materials and methods

Materials
Preparation of the anti-CD30-LDM
Anti-CD30-LDM was prepared in our laboratory and stored at À80 C. Briefly, the anti-CD30-LDP was cultured from growth medium of anti-CD30 antibody-expressing CHO cells and purified by protein G columns. The chromophore AE of LDM was separated by HPLC. Then, the AE-containing solution was mixed with the anti-CD30-LDP solution to form the enediyneintegrated ADC anti-CD30-LDM. Next, free AE was removed by ultrafiltration centrifugation. The composition of the ADC was finally confirmed by reverse-phase HPLC. For more detailed information, see literature [13] .
ELISA
The 96-well plates were coated with the different concentrations of recombinant CD30-Fc fusion protein (R&D Systems, Minneapolis, MN). After the wells were blocked with 2% BSA/ PBST (phosphate-buffered saline with Tween), anti-CD30-LDM was incubated at varying concentrations at 37 C for 1 h. Then, the wells were washed with PBST and incubated with an alkaline phosphatase goat anti-human IgG (Fab-specific) probe at 37 C. After substrate was added, the reaction was stopped. The optical density at 405 nm was determined using a microplate reader (Thermo Fisher Scientific, Waltham, MA).
Flow cytometry analysis
For antibody saturation binding, 3 Â 10 5 cells were incubated with increasing concentrations of anti-CD30-LDM for 1 h at 4 C, then washed twice with ice-cold staining medium to remove free mAbs, and incubated with 1: 100 FITCconjugated goat anti-human IgG for 1 h at 4 C. The labelled cells were washed and resuspended in PBS, and then MFI was determined by FACS Calibur (BD Biosciences, San Jose, CA).
Preparation of the 123 I-anti-CD30-LDM
Labelling 300 lL of pH 7.2 (0.05 M), 100 lL of antibody anti-CD30-LDM (10 mg/mL) and 100 lL of 1.11 GBq (30 mCi) Na 123 I (pH 7.0, High Tech of Atom Co. Ltd., Beijing, China) solution were added to the reaction tube containing 50 lg of Iodogen (Sigma-Aldrich, St. Louis, MO). The reaction mixture was incubated at 37 C for 40 min, and diluted with 1 ml water. The radio labelling efficiency was analyzed by size exclusion HPLC (see HPLC Analysis Section).
Purification
The radiolabeled antibody was purified on Sephadex PD10 Column (GE Healthcare UK Limited, Little Chalfont, UK). In brief, the Sephadex PD10 Column was washed with saline for 3 times. The mixture was applied to the Column, and then the Column was washed with 10 ml of saline. Each tube received 0.5 ml of the eluent, and the activity of the eluent was measured with a radioactivity metre to draw the elution curve. The radiochemical purity after purification was analyzed by size exclusion HPLC (see HPLC Analysis Section). The specific activity of 123 I-anti-CD30-LDM was calculated by the radioactivity after purification and quantification.
HPLC analysis
The radio labelling efficiency and radiochemical purity were analyzed by size exclusion HPLC on an Agilent 1260 system (Agilent Technologies, San Diego CA). HPLC systems were equipped with in-line ultraviolet (280 nm) and radiation detectors. A TSK gel G3000SWXL HPLC Column (7.8 mm Â 30.0 cm, TOSON Corporation, Tokyo, Japan) was used at a flow rate of 2 ml/min with pH 7.4 10 mM PBS solution. The radioactivity of the eluate was monitored using an in-line NaI radiodetector (Elysia-Raytest GmbH, Straubenhardt, Germany).
Octanol-Water partition coefficient (log P Octanol/water )
To determine the lipophilicity of 123 I-anti-CD30-LDM, approximately 18 million counts per minute of the radiolabeled antibody were diluted in 0.5 ml PBS. An equal volume of 1octanol was added to obtain a binary phase system. After stirred in a vortex mixer for 2 min, it was separated into 2 layers by centrifugation (3500 RPM, 5 min). 0.2 ml sample was taken from each layer, and radioactivity was measured in a well-type c-Counter (Beijing Nuclear Instrument Factory). Log
Stability
Approximately 37 MBq of 123 I-anti-CD30-LDM (0.1 ml) was added to 0.5 ml of foetal bovine serum (FBS) and saline. The samples were incubated at 37 C at approximately 3.5, 7, 15 and 24 h. An equal volume of acetonitrile was added and stirred in a vortex mixer, then followed by centrifugation at 3500 RPM for 5 min to pellet the precipitated serum proteins. The supernatant was analyzed on HPLC as described above (see HPLC Analysis Section).
Cell lines
The human anaplastic large cell lymphoma (ALCL) Karpas 299 cells were purchased from BIOPIKE (Beijing, China). The Burkitt lymphoma Raji cells were provided by our laboratory. Cells were grown in RPMI-1640 medium, supplemented with 10% FBS, and 100 units/mL of both penicillin and streptomycin. Cell lines were maintained in 5% CO 2 at 37 C.
Cellular binding assays
A serial dilutions of Karpas 299 and Raji cells were collected in the range of 10 Â 10 4 to 500 Â 10 4 cells in triplicate. Each tube was incubated with 123 I-anti-CD30-LDM ($14 KBq [$0.4 lCi]; $50 ng of proteins) in PBS containing 1% bovine serum albumin at room temperature for 2 h on an orbital shaker. Cells were washed 2 times with PBS, collected and counted using a gamma counter. The percentage of specifically bound 123 I activity was assessed by comparison with standards and controls.
Biodistribution in xenograft models
All animal experiments were conducted with approval from the Institutional Animal Care and Use Committee of the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, China. Female B-NDG mice (18-20 g, 6-8 weeks old) were obtained from Jiansu Biocytogen Co., Ltd (Nantong, China). Aliquots of cells (5 Â 10 6 ) of Karpas 299 and Raji cells were suspended in 200 lL of PBS and subcutaneously injected into the right flank of mice. Mice were monitored for general health and tumour growth and size every other day. The tumours developed for use for in vivo studies after 10-14 d, and the volume of tumour nodule is up to 300-500 mm 3 and ready for biodistribution studies.
Biodistribution studies were conducted to evaluate the uptake of 123 I-anti-CD30-LDM in mice bearing s.c. Karpas299 or Raji tumours. Mice were randomized into 4 groups (n ¼ 5) before the study and the tails of mice were warmed gently with a warm bath for 5 min before receiving 123 I-anti-CD30-LDM (740 KBq in 100 lL of 0.9% sterile saline for injection) via intravenous (i.v.) tail-vein injection (t ¼ 0 h). Animals (n ¼ 5, per group) were euthanized by CO 2 inhalation at 3.5 h, 7 h, 15 h and 24 h after injection, and tissues of interest (including the tumour) were removed, rinsed in water, dried in air for 5 min, weighed, and counted using a well-type gamma counter for accumulation of 123 I radioactivity. Count data were decay-corrected, and the percentage injected activity per gram (%ID/g) for each tissue sample was calculated by normalization to the total amount of activity injected.
Statistical analysis
The data are expressed as the mean ± SD. The statistical significance between two groups was determined using two-way ANOVA, followed by Student's t-test. For all tests, p values < .05 were considered statistically significant.
Results
Anti-CD30-LDM had high-affinity binding to CD30 antigen and CD30-positive cell lines Even though the biodistribution and metabolism of ADCs (anti-CD30-LDM) can be inferred from studies with antibodies alone (anti-CD30), there is evidence that these characteristics of ADCs may be different than that of pure antibodies [17] . We first detected the antigen-binding properties of anti-CD30-LDM. The binding of anti-CD30-LDM to recombinant human CD30 was assayed by ELISA. Anti-CD30-LDM showed a saturable dose-response curve as well as the anti-CD30-LDP (Figure 1(A) ). It indicated that the anti-CD30-LDM after the conjugation of AE kept the similar specific antigen-binding activity of anti-CD30-LDP.
The binding affinity to CD30þ Karpas 299 cells was further investigated by FACS. Measurement of the binding of anti-CD30-LDM after incubation at different concentrations with identical numbers of cells revealed a saturable dose-response curve similar to the anti-CD30-LDP (Figure 1(B) ). The results demonstrated that anti-CD30-LDM not only recognized CD30 antigen, but also had high-affinity and specific binding with native CD30 on the surface of lymphoma cells.
Radiolabeling and physical characterization of 123 I-anti-CD30-LDM
Initial labelling efficiency of the 123 I-anti-CD30-LDM at 37 C for 40 min, 2 h and 3.5 h was 20%, 30% and 59%, respectively (100 lg anti-CD30-LDM, 4-5 mCi Na 123 I and 50 lg Iodogen). However, when 1 mg of anti CD30-LDM and 555 MBq were used, labelling efficiency was increased to 70% under the conditions of 37 C for 40 min. HPLC chromatogram of labelling efficiency analysis was shown in Figure 2(A,B) . The elution curve of 123 I-anti-CD30-LDM on PD10 Column eluting with saline is shown in Figure 3 . The 123 I-anti-CD30-LDM was eluted firstly (tube 6 th to 8 th ), then unlabelled 123 I was eluted secondly (tube 11th to 17th). Finally, 123 I-anti-CD30-LDM was successfully prepared by this method, and the radiochemical yield was 45% (without correcting for decay). After purification by Sephadex PD-10 columns, 123 I-anti-CD30-LDM was formulated in sterile saline for injection with a radiochemical purity of more than 98%. The retention time of 123 I-anti-CD30-LDM was consistent with the unlabelled anti-CD30-LDM ( Figure 4 ) by HPLC analysis. The radioactivity concentration was 329 MBq/mL (8.9 mCi/mL). The specific activity was more than 240.5 MBq/mg (36.1 TBq/lmol) of protein. The total preparation time was 60 min.
To determine the lipophilicity of the radiolabeled antibody of 123 I-anti-CD30-LDM, the Octanol-water partition coefficient was determined. The Log P Octanol/Water value was -2.47 ± 0.03 (n ¼ 3), indicating that 123 I-anti-CD30-LDM has good water solubility.
Both stability of 123 I-anti-CD30-LDM on saline and FBS were tested when it was incubated at 37 C for 24 h. The radiochemical purity at 24 h was 97% in saline, and 94% in FBS ( Figure 5 ) compared with the original. The stability test showed there was not a significant deiodination process of 123 I-anti-CD30-LDM in vitro.
Cellular binding abilities of 123 I-anti-CD30-LDM
To confirm that the conjugation and 123 I-radiolabeling anti-CD30-LDM did not compromise antibody immunoreactivity, cellular binding assays were performed ( Figure 6 ). Briefly, different numbers of Karpas 299 and Raji cells were incubated with 123 I-anti-CD30-LDM for 2 h. Cells were then counted using a gamma counter. The percentage of specifically bound 123 I activity was calculated. The data revealed that as the numbers of CD30-positive Karpas299 cells increased (in the range of 10-500 Â 10 4 cells/tube), the binding of 123 I-anti-CD30-LDM also increased to more than 98% specifically binding activity. Control experiments using CD30-negative Raji cells showed no specific binding. Collectively, these data confirmed that 123 I-anti-CD30-LDM retained high immunoreactivity and specificity for native CD30 antigen on tumour cells.
Biodistribution data
Ex vivo biodistribution studies were conducted at 3.5, 7, 15 and 72 h after administration of 123 I-anti-CD30-LDM in separate groups of Karpas299 and Raji tumour-bearing mice. It was shown that the radiotracer displays a background distribution and tumour uptake (Table 1 and Figure 7 ). Tumour uptake in the CD30-positive Karpas299 model was 4.58 ± 1.06 percentage injected activity (%ID)/g at 24 h after administration. In contrast, accumulation of radioactivity in the Raji CD30-negative model was significantly lower, only 2.75 ± 0.47%ID/g at 24 after administration (p < .01 for comparisons between tumour models).
The highest accumulation of 123 I radioactivity among normal organs was found in the spleen, with 37.07 ± 5.29% ID/g at 3.5 h after injection in Karpas299 model. At 24 h after radiotracer administration, and spleen uptake of 123 I radioactivity was 12.05 ± 3.79% ID/g at 24 h in Karpas299 model, and 13.32 ± 1.56% ID/g in the CD30-negative Raji model, which was the same as in the CD30 positive model. Among other tissues, blood, heart, liver and bone showed higher accumulation of 123 I-anti-CD30-LDM. The uptake of thyroid to 123 I-anti-CD30-LDM was slightly increased from 3.5 to 24 h, which indicated in vivo deiodination of 123 I-anti-CD30-LDM was appeared within acceptable range.
The tumour to muscle ratios and tumour to blood ratios were gradually increased. Maximum values of tumour uptake for 123 I-anti-CD30-LDM in CD30 (þ) karpas299 models showed 2-fold higher than in CD30 (-) Raji models (Tumour/ Blood). The tumour/background ratios obtained after 24 h were the highest for 123 I-anti-CD30-LDM in Karpas299 model (Table 1 and Figure 8 , p < .01 for comparisons between tumour models).
Discussion
On the basis of clinical use of brentuximab vedotin, anti-CD30 ADCs offer a promising alternative treatment option for refractory Hodgkin lymphomas and non-Hodgkin lymphomas [18, 19] . Despite high response rates, many patients do not achieve complete remission and develop BV-resistant disease [20] [21] [22] . MMAE resistance has been reported as one of the BV resistance mechanisms explored from patients [9] . The novel type of ADC-anti-CD30-LDM, differed from the mechanism of MMAE. LDM does not block the polymerization of tubulin but exerts its cytotoxic effects through inducing DNA damage [23] . Therefore, we speculated that anti-CD30-LDM might have the potential to overcome resistance induced by BV. We had reported anti-CD30-LDM either alone or combination with crizotinib show excellent antitumor activities in CD30þ/ALK þ anaplastic large cell lymphoma both in vitro and in vivo [13, 16] . It indicated that anti-CD30-LDM could be a promising candidate for the treatment of CD30þ lymphomas.
To promote the clinical translational of anti-CD30-LDM, we would to further investigate the feasible use of isotope labelled with anti-CD30-LDM in the current study. By using the Iodogen method, 123 I-anti-CD30-LDM was found to be stable with high immunoreactivity in vitro. 123 I-anti-CD30-LDM was specifically taken up by CD30 (þ) Karpas299 cells at a much higher binding ratio than that in CD30 (À) Raji cells. Moreover, in the biodistribution study of tumour xenografts, obvious radioactivity could be detected in tumour area of CD30 (þ) Karpas299 tumour-bearing mice (4.98 ± 0.99%ID/g). However, for the radioactivity in tumour area of the CD30 (À) Raji tumour-bearing mice, the uptake is only 2.75 ± 0.47%ID/g. This biodistribution studies demonstrated that tumour uptake for 123 I-anti-CD30-LDM in CD30 (þ) models was 2-fold higher than in CD30 (À) models. The antibodies used in this experiment can be labelled easily and sufficient yields obtained with 123 I. We report here for the first time the biodistribution properties of 123 I-anti-CD30-LDM in the B-NDG mice engrafted with CD30 positive Karpas 299 cells and CD30 negative Raji cells. Only two previous reports have described CD30 radioimmunotherapy (RIT) in B-NDG mice. An important consideration in the design of RICs is the residence time in blood.
The restricted expression of CD30 limits non-specific background uptake in organs such as the spleen suggests a promising role for CD30-targeted RIT [24] . Therefore, some studies have attempted to target CD30 with RIT. The first feasibility study of treatment with 131 I-Ki-4 was used for the cell toxic beta-emitter in patients with refractory, advancedstage HL was completed in 2005 [25] . In animal model, 211 At radiolabeled HeFi-1 was very promising for the treatment of CD30-expressing leukemias and lymphomas, and the combination regimen of 211 At-HeFi-1 with unmodified HeFi-1 enhanced the therapeutic efficacy [26] . Another study with anti-CD30 RICs for treatment of HL was performed and published in 2010 [27] . In this study, by comparison of the binding affinity to a CD30-positive HL cell and biodistribution in HL bearing mice of anti-CD30 RICs of varying structure and labelling nuclides, they found in vitro tumour cell affinities of all RICs were promising. However, in vivo biokinetics tested in the mouse model did not meet expectations. Therefore, as a sensible supplementary therapy for treatment of HL, the development of more effective new anti-CD30 conjugates is very important. In the context of CD30-imaging radiotracer, Rylova et al. reported the anti-CD30 (AC-10) labelled with 89 Zr was a sensitive PET agent with high tumour-to-normaltissue contrast in HL model [24] . Kang et al. reported that 89 Zr-radiolabeled Brentuximab vedotin (BV) was developed for in vivo tracking of BV and imaging CD30 expression in lung cancer models [28] .
The main problem with the radioactive anti-CD30 mAbs, was their high and persistent radioactivity concentration in blood. It is known that a soluble form of CD30 (sCD30) is elevated in serum of patients with HL by shedding [29] . The extracellular, sCD30 produced by shedding is 90 kDa in size and can be bound either by anti-CD30 antibody or by the applied RICs [30, 31] . This was the decisive obstacle for application of the anti-CD30 RICs selected [27] . In our case, although blood uptake is higher up to 11.68 ± 3.40%ID/g at 3.5 h, but it graduated down to average 1.82 ± 0.88%ID/g in Karpas299 and 2.75 ± 0.47%ID/g in Raji at 24 h. Both the tumour/blood and the tumour/muscle ratio increase steadily over the course of time in karpas299 models. This will allow delivery of high doses of radiation precisely to the tumour while minimal doses to normal tissues. Data are mean %ID/g ± SD. Errors for tumour-to-tissue ratios are geometric mean of SD. n ¼ 5. In conclusion, anti-CD30-LDM can be labelled with 123 I easily and sufficient yields were obtained by our methods. After successful labelling and measurement of tumour and organ uptake for 123 I-anti-CD30-LDM, we conclude that 123 Ianti-CD30-LDM preserved specific binding to CD30 in vitro and uptake in tumour xenografts in B-NDG mice. Our research provides a basis of anti-CD30-LDM as a promising candidate for further clinical translational study targeting to CD30 positive lymphomas and other diseases.
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